scholarly journals Patient Satisfaction, Adherence , Compliance , Persistence in Healthcare . Preliminary Real-World Evidence (RWE) in a Private Health Insurance in Latin America Country

2018 ◽  
Vol 21 ◽  
pp. S139
Author(s):  
E Bregola ◽  
L Zimmer ◽  
J Lakoski ◽  
C Lima ◽  
D Bazzo ◽  
...  
Keyword(s):  
Latin America ◽  
Patient Satisfaction ◽  
Health Insurance ◽  
Real World ◽  
Private Health Insurance ◽  
Real World Evidence ◽  
Latin America Country

scholarly journals The Effect of an Orthopedic Hand Surgeon’s Attire on Patient Confidence and Trust

Hand ◽  
2018 ◽  
Vol 14 (5) ◽  
pp. 675-683 ◽  
Author(s):  
Vince W. Lands ◽  
Ajith Malige ◽  
Chinenye O. Nwachuku ◽  
Kristofer S. Matullo
Keyword(s):  
Patient Satisfaction ◽  
Health Insurance ◽  
Private Health Insurance ◽  
Clinical Skills ◽  
White Coat ◽  
Male And Female ◽  
Study Results ◽  
Outpatient Practice ◽  
Patient’S Perception ◽  
Patient Confidence

Background: Multiple studies have concluded that patients are more likely to understand and trust physicians who dress in more formal attire (shirt and tie) as opposed to casual attire (t-shirts and jeans). The white coat has repeatedly been reported as a major source of trust and confidence in a patient’s eyes. Methods: This study explores the effect an orthopedic hand surgeon’s attire has on a patient’s perception of their surgeon’s clinical values. All patients 18 years of age and older who visited our orthopedic hand surgeon’s suburban outpatient practice were asked to participate in our survey-based study. Results: Ninety-seven surveys were completed and included. A majority of our responders are female (n = 59, 60.8%), Caucasian (n = 83, 85.6%) between the ages of 55 and 74 years (n = 40, 41.2%), currently employed (n = 59, 60.8%) with private health insurance (n = 69, 71.1%), and married (n = 64, 66.0%). Patients rated male and female hand surgeons wearing a white coat highest using the Likert scale and when asked about their perceived clinical qualities. Patients consistently poorly rated their surgeons wearing casual attire. Patients did note that the white coat, or any specific attire, was not necessary during the initial encounter to build a strong patient-surgeon relationship. Finally, goatees and beards do not positively or negatively impact a surgeon’s patient-constructed image. Conclusions: Combining strong clinical skills with appropriate clinical attire highlighted by the physician wearing a white coat appears to be an effective way to enhance patient satisfaction while ultimately gaining the trust and respect needed to properly care for patients.

scholarly journals The use of antibiotics in the treatment of pediatric varicella patients: real-world evidence from the multi-country MARVEL study in Latin America & Europe

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Lara J. Wolfson ◽  
Marìa Esther Castillo ◽  
Norberto Giglio ◽  
Zsófia Mészner ◽  
Zsuzsanna Molnár ◽  
...  
Keyword(s):  
Latin America ◽  
Real World ◽  
Real World Evidence

PNS118 Real World Evidence (RWE) Use in Latin America Healthcare Decision Making: An Stakeholder Survey Analysis.

2021 ◽  
Vol 24 ◽  
pp. S194
Author(s):  
L. Costa ◽  
A.L. Hincapie ◽  
R. Gilardino ◽  
B. Tang ◽  
G. Julian ◽  
...  
Keyword(s):  
Decision Making ◽  
Latin America ◽  
Real World ◽  
Healthcare Decision ◽  
Survey Analysis ◽  
Healthcare Decision Making ◽  
Real World Evidence

scholarly journals Patient perceptions of the re-usable Respimat® Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study

2021 ◽  
Vol 18 ◽  
pp. 147997312098622
Author(s):  
Michael Dreher ◽  
David Price ◽  
Asparuh Gardev ◽  
Pascale Peeters ◽  
Satish Arora ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Patient Satisfaction ◽  
Pulmonary Disease ◽  
Real World ◽  
Chronic Obstructive ◽  
Plain Language ◽  
Open Label ◽  
Obstructive Pulmonary Disease ◽  
Real World Evidence ◽  
Assess Patient Satisfaction

The Respimat® Soft Mist™ inhaler (SMI) has recently been improved, with a re-usable device replacing the disposable version. Certain countries are currently phasing out the disposable inhaler. This study aimed to assess patient satisfaction with and preference for the re-usable device. This 4–6-week, multicentre, open-label, prospective, real-world, non-interventional study was conducted across six European countries. Patients with chronic obstructive pulmonary disease were enrolled between October and December 2019, in three cohorts: (1) currently using the re-usable Respimat SMI; (2) switched from disposable Respimat SMI at study entry; and (3) naïve to any Respimat SMI. Patients were assessed using the Patient Satisfaction and Preference Questionnaire (PASAPQ) and Ease of Handling Questionnaire. In total, 262 patients were enrolled. At follow-up, the mean PASAPQ score was 83.3/100 overall, with similar results across all three patient cohorts. Most patients were ‘satisfied’ or ‘very satisfied’ with the re-usable device. The overall score for willingness to continue using the device was 87.8/100. In total, 13 adverse events were recorded, none of which was classified as serious. This study provides real-world evidence for practitioners to start patients on Respimat re-usable, irrespective of a patient’s prior experience with this inhaler. Plain language summary: Inhalers are often used to treat patients with chronic obstructive pulmonary disease (COPD). However, there are many available, which can lead to confusion and poor inhaler technique. It is important for a patient to be happy with their inhaler. This study looked at how patients liked the re-usable Respimat® Soft Mist™ inhaler vs. their previous inhaler. It also asked whether they would be willing to continue using the device at the end of the study period.After 4–6 weeks of using the re-usable device, patients reported that they were happy with the inhaler and most would be willing to carry on using it.Overall, these results show that doctors can prescribe Respimat re-usable to patients, even if the patient has not used the inhaler before.

scholarly journals Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America

2019 ◽  
Vol 22 (6) ◽  
pp. 739-749 ◽  
Author(s):  
Nahila Justo ◽  
Manuel A. Espinoza ◽  
Barbara Ratto ◽  
Martha Nicholson ◽  
Diego Rosselli ◽  
...  
Keyword(s):  
Decision Making ◽  
Latin America ◽  
Case Studies ◽  
Real World ◽  
Healthcare Decision ◽  
Global Trends ◽  
Healthcare Decision Making ◽  
Real World Evidence

scholarly journals Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study

2019 ◽  
pp. 1-19
Author(s):  
Vania Tietsche de Moraes Hungria ◽  
Carlos Chiattone ◽  
Miguel Pavlovsky ◽  
Lina M. Abenoza ◽  
Gladys P. Agreda ◽  
...  
Keyword(s):  
Latin America ◽  
Latin American ◽  
Real World ◽  
B Cell Lymphoma ◽  
Patient Characteristics ◽  
Hematologic Malignancies ◽  
Treatment Patterns ◽  
Lymphocytic Leukemia ◽  
Real World Evidence

PURPOSE Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin American patients with MM, CLL, and NHL. METHODS This study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4). RESULTS Of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median follow-up was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. CONCLUSION The HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making.

Sign in / Sign up

Export Citation Format

Share Document